Business Context and Reporting Period
Company: HALOZYME THERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: January 9, 2017
Event: Regulation FD Disclosure regarding a corporate update and financial guidance presentation at the annual JP Morgan Healthcare Conference.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached presentation slides (Exhibit 99.1) which are incorporated by reference but not detailed in the body of this 8-K.
Material Changes
No material changes to financial results or operations are explicitly detailed in the text of this filing. The report serves to disclose the occurrence of the presentation and the availability of forward-looking information contained therein.
Guidance, Outlook, and Risks
- Guidance: Management provided financial guidance for the 2017 fiscal year during the January 9, 2017 presentation.
- Strategic Programs: The presentation included updates on certain strategic programs.
- Risks and Uncertainties: The filing references page 2 of the attached presentation (Exhibit 99.1) for a discussion of forward-looking statements and associated risks.
- Legal Status: The information is furnished under Item 7.01 and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Corporate Update Presentation) for specific 2017 financial guidance figures.
- Examine page 2 of Exhibit 99.1 for detailed risk factors and assumptions underlying forward-looking statements.
- Verify the details of the strategic program updates mentioned in the presentation slides.